High expression of CD39 in gastric cancer reduces patient outcome following radical resectionXiaoyan Cai(Cotton Research Institute), Yihong Sun(South China Agricultural University)Oncology LettersSeptember 26, 201610.3892/ol.2016.5189Cited by 57SaveCiteExport RISWatch citationsRelated PapersPerioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial|The Lancet Oncology|2021|436The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction|Nature Communications|2022|82